ClinicalTrials.gg
Not yet recruitingNCT07824154Updated Sep 17, 2026

Diabetes Prevention AI: Enhancing Prevention Strategies Using Personalized Nutrition and Fitness Coaching for the Next Generation

An interventional study of AI-Powered Diabetes Prevention Chatbot in Pre Diabetes and Type2 Diabetes, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study is testing an artificial intelligence (AI) chatbot designed to help adults at risk for type 2 diabetes adopt healthier lifestyles. The chatbot provides personalized and culturally tailored guidance on nutrition, physical activity, resistance training, and goal setting. About 30 adults aged 18 to 55 years will use the chatbot for 6 weeks and provide feedback through surveys and interviews.

Researchers will evaluate whether the chatbot is easy to use, helpful, and trustworthy, and whether data about changes in health behaviors can be feasibly collected, in order to inform larger future studies to improve diabetes prevention.

Read the detailed description

Type 2 diabetes continues to be a major public health concern, with growing evidence that individuals with normal body weight may also be at increased risk of developing prediabetes and type 2 diabetes. Existing diabetes prevention programs have primarily targeted individuals with overweight or obesity, creating a need for innovative prevention approaches tailored to younger, normal-weight, and culturally diverse populations.

This study will evaluate a novel artificial intelligence (AI)-powered chatbot designed to deliver personalized, culturally tailored diabetes prevention support. The intervention combines evidence-based nutrition and physical activity guidance with conversational AI technology to provide accessible lifestyle coaching focused on diabetes risk reduction. The chatbot incorporates expert-validated educational content and behavioral support strategies intended to promote healthy habits and sustained engagement.

The chatbot was developed using a curated knowledge base of culturally adapted diabetes prevention recommendations. Personalized guidance is generated using participant preferences, context, and validated educational resources to support lifestyle behaviors associated with improved metabolic health. The platform is intended to provide scalable, user-centered support while maintaining alignment with established diabetes prevention principles.

This pilot study will assess the feasibility and acceptability of implementing an AI-enabled diabetes prevention intervention in a real-world setting. Researchers will evaluate user experiences with the chatbot, including engagement, satisfaction, trust, usability, and perceptions of cultural relevance. Findings will inform future development of digital health interventions and support the design of larger studies aimed at evaluating the effectiveness of AI-assisted approaches for diabetes prevention and health equity.

02

Conditions studied

  • Pre Diabetes
  • Type2 Diabetes

Browse trials for

Keywords

  • Lifestyle Intervention
  • Generative AI
  • Digital Health
  • Health Coaching
  • Preventive Health
  • Health Equity
  • Culturally Tailored Intervention
03

In context

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

This study's planned enrollment of 30 is below the median of 56 across 661 interventional studies indexed under Glucose Intolerance.

Browse Glucose Intolerance studies →

Lead sponsor

Emory University is the lead sponsor of 1,405 studies on the registry; 225 are open to participants now.

Of its 237 completed or terminated interventional studies of FDA-regulated products, 178 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have at least one of the following diabetes risk factors:

    • of 5.7-6.4%
    • of 18.5 - 24.9 kg/m\^2
    • Fasting plasma glucose 100 - 125 mg/dL
    • Family history of type 2 diabetes in first-degree relatives (parents, siblings, or children)
    • History of gestational diabetes
    • Membership in a high-risk ethnic group (African American, Hispanic, Native American, Asian American, Pacific Islander)
  • Access to a smartphone or computer with internet
  • English reading and writing proficiency
  • Be willing to use the chatbot at least 3 times per week
  • Be able to provide
  • Availability for the 6-week study duration
  • Able to perform resistance training exercises

Exclusion criteria

Exclusion Criteria:

  • Are diagnosed with type 1 or type 2 diabetics
  • Have uncontrolled hypertension (higher than 160/100 mmHg)
  • Have cardiovascular disease
  • Are pregnant or planning to be pregnant
  • Are actively undergoing treatment for cancer
  • Have an eating disorder
  • Have chronic kidney disease
  • Are enrolled in another research study or participating in a structured lifestyle program
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    AI-Powered Diabetes Prevention Chatbot

    Participants will receive access to an artificial intelligence (AI)-powered chatbot that provides personalized, culturally tailored diabetes prevention guidance focused on nutrition, resistance training, goal setting, and lifestyle behavior change for a 6-week intervention period.

    Behavioral: AI-Powered Diabetes Prevention Chatbot

Interventions

  • BehavioralAI-Powered Diabetes Prevention Chatbot

    Participants will use a generative AI chatbot designed to provide personalized, evidence-based diabetes prevention support. The chatbot delivers culturally tailored nutrition and physical activity recommendations, with an emphasis on high-protein dietary strategies, resistance training, goal setting, motivational support, and healthy lifestyle behaviors. Participants will be encouraged to interact with the chatbot at least three times per week during the 6-week study period. Recommendations are generated using expert-validated diabetes prevention content and personalized according to participant characteristics and preferences.

06

What researchers measure

Primary outcomes

  1. Feasibility and Acceptability: Task completion rate

    The proportion of recommended chatbot activities, goals, or behavioral tasks completed by participants during the 6-week intervention period, as assessed through chatbot analytics. This measure will be used to evaluate participant engagement and adherence to chatbot-delivered recommendations.

    Time frame: Baseline, 6 weeks

  2. Feasibility and Acceptability: Conversation length

    Average number of messages exchanged between participants and the AI chatbot during each interaction session over the study period. Conversation length will be obtained from chatbot analytics and used as an indicator of participant engagement with the intervention. Longer conversations may reflect greater interaction with chatbot-delivered nutrition, physical activity, and lifestyle coaching content

    Time frame: Baseline, 6 weeks

Secondary outcomes

  1. Feasibility: Body Mass Index (BMI)

    Proportion of participants for whom self-reported body mass index (BMI, kg/m²) is successfully collected at baseline and at the end of the 6-week intervention period. BMI will be calculated using participant-reported height and weight collected through study surveys.

    Time frame: Baseline, 6 weeks

  2. Feasibility: Physical Activity Behaviors

    Proportion of participants for whom self-reported physical activity behaviors, including engagement in resistance training and overall activity levels, will be successfully collected through study questionnaires and chatbot interaction data.

    Time frame: Baseline, 6 weeks

  3. Feasibility: Dietary Behaviors

    Proportion of participants for whom self-reported dietary intake and nutrition-related behaviors, including the adoption of higher-protein dietary practices and other healthy eating behaviors promoted by the chatbot intervention, are successfully collected. Data will be collected through participant surveys and chatbot interaction records.

    Time frame: Baseline, 6 weeks

  4. Feasibility: Behavioral Intention for Diabetes Prevention

    Proportion of participants with successfully recorded self-reported intention and readiness to engage in healthy lifestyle behaviors for diabetes prevention, including dietary modifications and physical activity, as assessed through study questionnaires

    Time frame: Baseline, 6 weeks

  5. Perceived Trustworthiness of the Chatbot

    Participant-reported trust in the accuracy, reliability, and credibility of information and recommendations provided by the AI chatbot, assessed through study questionnaires.

    Time frame: Baseline, 6 weeks

  6. Ease of Use: System Usability Scale (SUS)

    The SUS is a 10-item questionnaire that assesses participants' perceived usability of the application. Each item is rated on a 5-point response scale. Responses are scored using the standard SUS scoring method to generate a total score ranging from 0 to 100, with higher scores indicating greater perceived usability.

    Time frame: Baseline

  7. NASA Task Load Index (NASA-TLX)

    The NASA-TLX assesses participants' perceived cognitive workload while using the application across six domains: mental demand, physical demand, temporal demand, perceived performance, effort, and frustration. An overall workload score will be calculated from the domain ratings. Scores range from 0 to 100, with higher scores indicating greater perceived workload or task demand.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: After study completion

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07824154
Lead sponsor
Emory University
Collaborators
Georgia Center for Diabetes Translation Research
Responsible party
Megha Kumudchandra Shah (Associate Professor, Emory University) — Principal investigator
First posted
Sep 17, 2026
Start date
Oct 2026 (estimated)
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Megha K Shah, M.D., M.Sc.
Contact
mkshah@emory.edu
404-778-6944
Megha Shah, M.D., M.Sc.
principal investigator · Emory University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion